New drug boosts kidney transplant acceptance
Experimental data has shown that a new drug from Eliadom, called Tigoprobar, outperforms the standard treatment Tacrolimus in protecting kidney function in kidney transplant patients. Patients treated with Tigoprobar exhibited improved kidney function and no cases of acute rejection six months post-surgery, with side effects occurring at a rate 2% lower than the 12% observed in the Tacrolimus group. Eliadom will conduct advanced clinical trials to further evaluate the drug's effectiveness on a larger scale.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)